Showing results (241-250 of 439) with videos related to
Sort By:
Pageof 44
Heart (British Cardiac Society)|April 20, 2006
Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trialP A Poole-Wilson, S J Pocock, K A A Fox, et al.Journal of the American College of Cardiology|March 19, 2021
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced TrialMilton Packer, Stefan D Anker, Javed Butler, et al.European Heart Journal|May 19, 2016
Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-studyChristoph K Naber, Philip Urban, Paul J Ong, et al.Journal of the American College of Cardiology|October 7, 2017
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMIGennaro Giustino, Roxana Mehran, George D Dangas, et al.European Journal of Heart Failure|April 16, 2023
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trialAbhinav Sharma, João Pedro Ferreira, Faiez Zannad, et al.European Heart Journal|October 13, 2005
Predictors of mortality and morbidity in patients with chronic heart failureStuart J Pocock, Duolao Wang, Marc A Pfeffer, et al.European Heart Journal|August 26, 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programmeFaiez Zannad, João Pedro Ferreira, Javed Butler, et al.Heart (British Cardiac Society)|September 21, 2011
Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trialsPeter Damman, Tim Clayton, Lars Wallentin, et al.European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.The New England Journal of Medicine|April 5, 2016
Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial FibrillationKarl-Heinz Kuck, Josep Brugada, Alexander Fürnkranz, et al.Pageof 44